Professor of Genetics in the Department of Biomedical Sciences Mercer University School of Medicine, Savannah. He is Co-founder of SynPloid Biotek, LLC, currently known as CarryGenes Bioengineering, and previously was Director of Chromosome Engineering, Chromos Molecular Systems, Inc., and Scientific Founder and Senior Scientist, Iconix Pharmaceuticals, Inc. He has received research grants from Defense Advanced Research Program Agency (DARPA) to develop advanced tools for mammalian genome engineering, as well as the National Cancer Institute and other NIH agencies. He was awarded as a Georgia Cancer Coalition Distinguished Cancer Scholar in 2008.

Co-founder and Managing Partner of SynPloid Biotek, LLC, currently known as CarryGenes Bioengineering, a company founded in 2013 with support from the Defense Advanced Research Program Agency (DARPA). She has a background as Manager Intellectual Property and Business Development, Chromos Molecular Systems Inc. She previously served as Assistant Professor, Biomedical Sciences Department, Mercer University School of Medicine

Mr Dreyer has served as CarryGenes Executive Vice President and Chief Business Officer since 2019. He was the Dean and CEO of the biggest private Business School in Scandinavia and previously a Guest Professor of Tsinghua University Beijing. Mr Dreyer has served as management consultant at Baine, Deloitte and SIAR/Bossard. Later CEO of Business Research Ltd, with consulting operation in Asia and Europe. Mr Dreyer is also the Chairman of CarryGenes Oncology AB.

Mr Batcheller has an extensive background as CEO and Chairman of several life science companies such as Xintela AB, Saga Diagnostics AB, ImmuneBiotech AB and Immodulate Pharma AB. He has a strong track record in the life science industry as a serial entrepreneur, executive decision maker, strategic advisor, board member, dealmaker, and commercial lawyer. Greg has worked with the Business Research group in Asia and Europe since 2014 as a partner and senior advisor

Professor of Genetics in the Department of Biomedical Sciences Mercer University School of Medicine, Savannah. He is Co-founder of SynPloid Biotek, LLC, currently known as CarryGenes Bioengineering, and previously was Director of Chromosome Engineering, Chromos Molecular Systems, Inc., and Scientific Founder and Senior Scientist, Iconix Pharmaceuticals, Inc. He has received research grants from Defense Advanced Research Program Agency (DARPA) to develop advanced tools for mammalian genome engineering, as well as the National Cancer Institute and other NIH agencies. He was awarded as a Georgia Cancer Coalition Distinguished Cancer Scholar in 2008.

Co-founder and Managing Partner of SynPloid Biotek, LLC, currently known as CarryGenes Bioengineering, a company founded in 2013 with support from the Defense Advanced Research Program Agency (DARPA). She has a background as Manager Intellectual Property and Business Development, Chromos Molecular Systems Inc. She previously served as Assistant Professor, Biomedical Sciences Department, Mercer University School of Medicine

Mr Dreyer has served as CarryGenes Executive Vice President and Chief Business Officer since 2019. He was the Dean and CEO of the biggest private Business School in Scandinavia and previously a Guest Professor of Tsinghua University Beijing. Mr Dreyer has served as management consultant at Baine, Deloitte and SIAR/Bossard. Later CEO of Business Research Ltd, with consulting operation in Asia and Europe. Mr Dreyer is also the Chairman of CarryGenes Oncology AB.

Mr Holm has served as the CEO of Stora Cell AB (today StoraEnso), CEO of Lhoist group Belgien, PAI partner (leading European PE firm), CEO Perstorp Group, CEO and Chairman of the Board BillerudKorsnäs. Lennart has also been working with venture investments as a business angel in companies as Nexam Chemical AB (advanced organic chemistry / crosslinker technology) Polygiene AB (branded environmentally friendly / water saving anti-bacteria/virus additive). He is also member of the prestigious Royal Swedish Academy of Engineering Sciences (IVA).

He has served as Chairman in several Life Science companies such as Ambria Dermatology AB, Adenovir Pharma AB and Ellen AB. He has a long experience of capitalization and refinancing of life science organisations as doing well as financial due diligence.

Previous Vice President, Head of Clinical Research, Astra Hässle, Vice President, Head of GITA, AstraZeneca and Senior Vice President, Head of Global Development, 2002-2004 Novo Nordisk A/S, Denmark. And was also Vice President, Head of Global Clinical Development, UCB, Brussels Belgium. He has extensive professional experience form TRUEPOINT, Boston, USA and Fenix Centre for Research on Knowledge & Business creation and also a long list of publications.

He has experience of development of compound from early preclinical stage to first in human study. With a long background from life science industry as CEO and COO in several companies, such as NeuroVive Pharmaceuticals, Lipipeptides Ab and Schering-Plough AB.

More than 35 years of experience from the capital market. Previously active in e.g., a. PK Banken (today Norda), Jacobsson & Ponsbach Fondkommission, Invik & Co (Kinnevik) and JP Nordiska Fondkommission. Mr Fromholtz has a strong and deep understanding of corporate finance issues.